Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
about
The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis
P2860
Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Adding fast-acting insulin asp ...... abel, phase 3 trial (onset 3).
@en
Adding fast-acting insulin asp ...... abel, phase 3 trial (onset 3).
@nl
type
label
Adding fast-acting insulin asp ...... abel, phase 3 trial (onset 3).
@en
Adding fast-acting insulin asp ...... abel, phase 3 trial (onset 3).
@nl
prefLabel
Adding fast-acting insulin asp ...... abel, phase 3 trial (onset 3).
@en
Adding fast-acting insulin asp ...... abel, phase 3 trial (onset 3).
@nl
P2093
P2860
P921
P356
P1476
Adding fast-acting insulin asp ...... label, phase 3 trial (onset 3)
@en
P2093
Devjit Tripathy
Marek Demissie
Maricela Vidrio Velázquez
Milivoj Piletič
Søren C Tamer
P2860
P304
P356
10.1111/DOM.12955
P577
2017-07-06T00:00:00Z